Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-59
Closed -$13.5K 1420
2025
Q4
$13.5K Buy
59
+57
+2,850% +$13K ﹤0.01% 1427
2025
Q3
$463 Sell
2
-6,099
-100% -$1.24M ﹤0.01% 1422
2025
Q2
$1.13M Sell
6,101
-3,217
-35% -$598K 0.01% 764
2025
Q1
$1.95M Buy
+9,318
New +$1.81M 0.02% 668
2023
Q3
Sell
-20,007
Closed -$2.7M 927
2023
Q2
$2.7M Buy
+20,007
New +$2.93M 0.03% 313
2022
Q4
Sell
-3,283
Closed -$441K 1090
2022
Q3
$441K Sell
3,283
-21,668
-87% -$3.11M 0.01% 905
2022
Q2
$3.82M Buy
+24,951
New +$3.81M 0.06% 338
2021
Q4
Sell
-22,097
Closed -$2.38M 1135
2021
Q3
$2.38M Buy
22,097
+11,200
+103% +$1.28M 0.03% 419
2021
Q2
$1.23M Sell
10,897
-8,447
-44% -$951K 0.02% 475
2021
Q1
$2.09M Buy
19,344
+10,981
+131% +$1.17M 0.05% 319
2020
Q4
$896K Sell
8,363
-16,049
-66% -$1.54M 0.01% 296
2020
Q3
$2.14M Buy
+24,412
New +$2.3M 0.04% 151
2020
Q2
Sell
-17,254
Closed -$1.3M 586
2020
Q1
$1.3M Buy
17,254
+997
+6% +$84.9K 0.06% 117
2019
Q4
$1.44K Buy
+16,257
New +$1.35M ﹤0.01% 167
2018
Q3
Sell
-4,417
Closed -$409K 344
2018
Q2
$409K Sell
4,417
-30,607
-87% -$2.99M 0.02% 299
2018
Q1
$3.39M Hold
35,024
0.35% 47
2017
Q4
$3.39M Buy
+35,024
New +$3.3M 0.35% 47
2017
Q3
Sell
-42,559
Closed -$3.09M 310
2017
Q2
$3.09M Buy
42,559
+1,566
+4% +$105K 0.19% 102
2017
Q1
$2.67M Buy
40,993
+37,515
+1,079% +$2.36M 0.26% 70
2016
Q4
$217K Sell
3,478
-1,165
-25% -$71.1K 0.03% 308
2016
Q3
$292K Sell
4,643
-11,342
-71% -$734K 0.03% 309
2016
Q2
$990K Buy
15,985
+7,364
+85% +$449K 0.15% 194
2016
Q1
$492 Buy
+8,621
New +$481K 0.05% 275
2015
Q4
Sell
-173,957
Closed -$9.46M 219
2015
Q3
$9.46M Buy
173,957
+154,948
+815% +$10.1M 1.03% 22
2015
Q2
$1.28M Buy
19,009
+544
+3% +$35.5K 0.16% 191
2015
Q1
$1.08M Sell
18,465
-10,854
-37% -$656K 0.15% 180
2014
Q4
$1.92M Buy
29,319
+15,782
+117% +$995K 0.25% 95
2014
Q3
$782K Buy
+13,537
New +$752K 0.06% 151

Other funds holding ABBV

LMR Partners's ABBV Position: Q1 2026 in Review

LMR Partners sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 59 shares — an estimated $13.5K sold.

LMR Partners first reported a position in ABBV in Q3 2014 and held it in 28 quarters. The position peaked at $9.46M in Q3 2015. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • LMR Partners reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • LMR Partners sold 59 AbbVie shares in Q1 2026, an estimated $13.5K.
  • LMR Partners first reported a position in AbbVie in Q3 2014 and held it in 28 quarters.
  • LMR Partners's AbbVie position peaked at $9.46M in Q3 2015.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.